Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Update on BTK Inhibitors
2024 ASCO Annual Meeting
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for patients with high-risk relapsed or refractory chronic lymphocytic leukemia. It offers delayed disease progression and favorable survival and response, compared with alternative BTK inhibitors (Abstract 7048).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
At the ASCO meeting, we presented data on Network meta-analysis comparing the efficacy of covalent BTK inhibitors for treatment of relapsed refractory CLL. As the background, there are three covalent BTK inhibitors currently approved for CLL, and we do have some randomized trials comparing some of these drugs. For example, acalabrutinib was compared to ibrutinib in the relapse setting in Elevate RR study, and zanubrutinib was compared to ibrutinib in the Alpine trial. However, we don't have a comparison between the two second-generation covalent BTK inhibitors, zanubrutinib and acalabrutinib. There has been an effort recently to indirectly compare the efficacy of this drug through methods like matching adjusted indirect comparison or MAIC. Here we are using another methodology for this indirect comparison called Network meta-analysis, and this is a technique that gives us the opportunity of comparing multiple interventions and use both direct and indirect comparisons. So here we use three clinical trials after going through the inclusion criteria for different trials, and we used Alpine, which compared zanubrutinib versus ibrutinib.
We used Elevate RR, which compared acalabrutinib versus ibrutinib, and we also used Ascend trial which compared acalabrutinib versus chemotherapy. And the findings were summarized and in brief, when we looked at the overall response, zanubrutinib was superior to ibrutinib in terms of overall response, the CR rate was not as statistically significant. Also in terms of the overall response and CR rate comparison between zanubrutinib and ibrutinib while there was a trend in favor of zanubrutinib this was not as statistically significant. We also looked at progression free survival, and we did it by adjusting for COVID-19 and also presented the unadjusted comparison. So in the high risk population defined by each clinical trial, zanubrutinib was found to be superior to both ibrutinib and acalabrutinib and also chemo immunotherapy through this PFS analysis. And that was true whether or not we adjusted for COVID-19 or not. When we limited the analysis to only patients with del(17p), zanubrutinib remained superior to ibrutinib and chemo immunotherapy.
And also zanubrutinib in the adjusted analysis, but on the unadjusted analysis there was no statistically difference between zanubrutinib and acalabrutinib. And we also looked at overall survival. And while there was a trend in favor of zanubrutinib, this was not a statistically significant. So overall, this is an important study in providing another piece of data and evidence for both clinicians and investigators to put it next to the other analysis that we have recently done and others have done. I would like to remind ourselves that the gold standard remains to be randomized to have clinical trials, and in the absence of direct comparison, we can use methods like MAIC or MET Network meta-analysis to give us a better understanding of the efficacy.
Related Videos
The ASCO Post Staff
Jens Marquardt, MD, of the University of Lübeck, and Jens Hoeppner, MD, of the University of Bielefeld, discuss findings from the ESOPEC trial, which showed that perioperative chemotherapy (fluorouracii, leucovorin, oxaliplatin, docetaxel) and surgery improves survival in patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation (41.4 Gy plus carboplatin and paclitaxel) followed by surgery (LBA1).
The ASCO Post Staff
Jean-Marc Classe, MD, PhD, of France’s Nantes Université, discusses phase III results showing that systematic lymphadenectomy should be omitted in patients with advanced epithelial ovarian cancer with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery (LBA5505).
The ASCO Post Staff
Peter Riedell, MD, of The University of Chicago, discusses phase III findings on the regimen of brentuximab vedotin in combination with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This therapy demonstrated a survival advantage in the third-line setting, but as this is an interim analysis, questions remain regarding long-term safety and duration of response, according to Dr. Riedell (Abstract LBA7005).
The ASCO Post Staff
Don S. Dizon, MD, of Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, discusses final phase II results of the BrUOG 354 trial showing that, for patients with ovarian and other extrarenal clear cell cancers, nivolumab and ipilimumab warrant further evaluation against standard treatment, given the historically chemotherapy-resistant nature of the disease (LBA5500).
The ASCO Post Staff
Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly diagnosed multiple myeloma who are transplant-ineligible, may reduce the risk of disease progression or death by 40.4% vs VRd alone (Abstract 7500).